JP5951506B2 - プリン誘導体の結晶性形態 - Google Patents

プリン誘導体の結晶性形態 Download PDF

Info

Publication number
JP5951506B2
JP5951506B2 JP2012549413A JP2012549413A JP5951506B2 JP 5951506 B2 JP5951506 B2 JP 5951506B2 JP 2012549413 A JP2012549413 A JP 2012549413A JP 2012549413 A JP2012549413 A JP 2012549413A JP 5951506 B2 JP5951506 B2 JP 5951506B2
Authority
JP
Japan
Prior art keywords
crystalline
compound
tartrate
salt
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012549413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518041A5 (enExample
JP2013518041A (ja
Inventor
ベンジャミン マーク スケッド
ベンジャミン マーク スケッド
クリストファー ピーター ウォラル
クリストファー ピーター ウォラル
ジョナサン チャールズ クリスチャン アサートン
ジョナサン チャールズ クリスチャン アサートン
ジュリアン スコット ノーゼン
ジュリアン スコット ノーゼン
フィリッペ ファーナンデス
フィリッペ ファーナンデス
Original Assignee
サイクラセル リミテッド
サイクラセル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイクラセル リミテッド, サイクラセル リミテッド filed Critical サイクラセル リミテッド
Publication of JP2013518041A publication Critical patent/JP2013518041A/ja
Publication of JP2013518041A5 publication Critical patent/JP2013518041A5/ja
Application granted granted Critical
Publication of JP5951506B2 publication Critical patent/JP5951506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • C07C51/412Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01FMEASURING VOLUME, VOLUME FLOW, MASS FLOW OR LIQUID LEVEL; METERING BY VOLUME
    • G01F1/00Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow
    • G01F1/05Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using mechanical effects
    • G01F1/10Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using mechanical effects using rotating vanes with axial admission
    • G01F1/115Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using mechanical effects using rotating vanes with axial admission with magnetic or electromagnetic coupling to the indicating device
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01PMEASURING LINEAR OR ANGULAR SPEED, ACCELERATION, DECELERATION, OR SHOCK; INDICATING PRESENCE, ABSENCE, OR DIRECTION, OF MOVEMENT
    • G01P3/00Measuring linear or angular speed; Measuring differences of linear or angular speeds
    • G01P3/42Devices characterised by the use of electric or magnetic means
    • G01P3/44Devices characterised by the use of electric or magnetic means for measuring angular speed
    • G01P3/48Devices characterised by the use of electric or magnetic means for measuring angular speed by measuring frequency of generated current or voltage
    • G01P3/4802Devices characterised by the use of electric or magnetic means for measuring angular speed by measuring frequency of generated current or voltage by using electronic circuits in general
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01PMEASURING LINEAR OR ANGULAR SPEED, ACCELERATION, DECELERATION, OR SHOCK; INDICATING PRESENCE, ABSENCE, OR DIRECTION, OF MOVEMENT
    • G01P5/00Measuring speed of fluids, e.g. of air stream; Measuring speed of bodies relative to fluids, e.g. of ship, of aircraft
    • G01P5/02Measuring speed of fluids, e.g. of air stream; Measuring speed of bodies relative to fluids, e.g. of ship, of aircraft by measuring forces exerted by the fluid on solid bodies, e.g. anemometer
    • G01P5/06Measuring speed of fluids, e.g. of air stream; Measuring speed of bodies relative to fluids, e.g. of ship, of aircraft by measuring forces exerted by the fluid on solid bodies, e.g. anemometer using rotation of vanes
    • G01P5/07Measuring speed of fluids, e.g. of air stream; Measuring speed of bodies relative to fluids, e.g. of ship, of aircraft by measuring forces exerted by the fluid on solid bodies, e.g. anemometer using rotation of vanes with electrical coupling to the indicating device
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Aviation & Aerospace Engineering (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Fluid Mechanics (AREA)
  • Electromagnetism (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2012549413A 2010-01-22 2011-01-24 プリン誘導体の結晶性形態 Active JP5951506B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1001075.9A GB201001075D0 (en) 2010-01-22 2010-01-22 Crystalline forms
GB1001075.9 2010-01-22
PCT/GB2011/000087 WO2011089401A1 (en) 2010-01-22 2011-01-24 Crystalline forms of a purine derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016026263A Division JP6114849B2 (ja) 2010-01-22 2016-02-15 プリン誘導体の結晶性形態

Publications (3)

Publication Number Publication Date
JP2013518041A JP2013518041A (ja) 2013-05-20
JP2013518041A5 JP2013518041A5 (enExample) 2014-03-06
JP5951506B2 true JP5951506B2 (ja) 2016-07-13

Family

ID=42045946

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549413A Active JP5951506B2 (ja) 2010-01-22 2011-01-24 プリン誘導体の結晶性形態
JP2016026263A Active JP6114849B2 (ja) 2010-01-22 2016-02-15 プリン誘導体の結晶性形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016026263A Active JP6114849B2 (ja) 2010-01-22 2016-02-15 プリン誘導体の結晶性形態

Country Status (11)

Country Link
US (2) US8889861B2 (enExample)
EP (2) EP2526101B1 (enExample)
JP (2) JP5951506B2 (enExample)
KR (2) KR101927083B1 (enExample)
CN (2) CN102985423B (enExample)
ES (2) ES2694289T3 (enExample)
GB (1) GB201001075D0 (enExample)
PL (2) PL3150602T3 (enExample)
SG (2) SG10201500451TA (enExample)
TR (1) TR201816159T4 (enExample)
WO (1) WO2011089401A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8608797B2 (en) 2005-03-17 2013-12-17 Valtech Cardio Ltd. Mitral valve treatment techniques
US8333777B2 (en) 2005-04-22 2012-12-18 Benvenue Medical, Inc. Catheter-based tissue remodeling devices and methods
US11259924B2 (en) 2006-12-05 2022-03-01 Valtech Cardio Ltd. Implantation of repair devices in the heart
US9974653B2 (en) 2006-12-05 2018-05-22 Valtech Cardio, Ltd. Implantation of repair devices in the heart
US11660190B2 (en) 2007-03-13 2023-05-30 Edwards Lifesciences Corporation Tissue anchors, systems and methods, and devices
US8382829B1 (en) 2008-03-10 2013-02-26 Mitralign, Inc. Method to reduce mitral regurgitation by cinching the commissure of the mitral valve
EP2296744B1 (en) 2008-06-16 2019-07-31 Valtech Cardio, Ltd. Annuloplasty devices
ES2873182T3 (es) 2008-12-22 2021-11-03 Valtech Cardio Ltd Dispositivos de anuloplastia ajustables
US10517719B2 (en) 2008-12-22 2019-12-31 Valtech Cardio, Ltd. Implantation of repair devices in the heart
US8715342B2 (en) 2009-05-07 2014-05-06 Valtech Cardio, Ltd. Annuloplasty ring with intra-ring anchoring
US8241351B2 (en) 2008-12-22 2012-08-14 Valtech Cardio, Ltd. Adjustable partial annuloplasty ring and mechanism therefor
US8911494B2 (en) 2009-05-04 2014-12-16 Valtech Cardio, Ltd. Deployment techniques for annuloplasty ring
US8353956B2 (en) 2009-02-17 2013-01-15 Valtech Cardio, Ltd. Actively-engageable movement-restriction mechanism for use with an annuloplasty structure
US9968452B2 (en) 2009-05-04 2018-05-15 Valtech Cardio, Ltd. Annuloplasty ring delivery cathethers
US12485010B2 (en) 2009-05-07 2025-12-02 Edwards Lifesciences Innovation (Israel) Ltd. Multiple anchor delivery tool
US9180007B2 (en) 2009-10-29 2015-11-10 Valtech Cardio, Ltd. Apparatus and method for guide-wire based advancement of an adjustable implant
US10098737B2 (en) 2009-10-29 2018-10-16 Valtech Cardio, Ltd. Tissue anchor for annuloplasty device
WO2011067770A1 (en) 2009-12-02 2011-06-09 Valtech Cardio, Ltd. Delivery tool for implantation of spool assembly coupled to a helical anchor
US8870950B2 (en) 2009-12-08 2014-10-28 Mitral Tech Ltd. Rotation-based anchoring of an implant
GB201001075D0 (en) 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
US11653910B2 (en) 2010-07-21 2023-05-23 Cardiovalve Ltd. Helical anchor implantation
US10792152B2 (en) 2011-06-23 2020-10-06 Valtech Cardio, Ltd. Closed band for percutaneous annuloplasty
EP3725269A1 (en) 2011-06-23 2020-10-21 Valtech Cardio, Ltd. Closure element for use with annuloplasty structure
US8858623B2 (en) 2011-11-04 2014-10-14 Valtech Cardio, Ltd. Implant having multiple rotational assemblies
EP3970627B1 (en) 2011-11-08 2023-12-20 Edwards Lifesciences Innovation (Israel) Ltd. Controlled steering functionality for implant-delivery tool
EP2886084B1 (en) 2011-12-12 2018-02-14 David Alon Heart valve repair device
CA2885354A1 (en) 2012-09-29 2014-04-03 Mitralign, Inc. Plication lock delivery system and method of use thereof
US9949828B2 (en) 2012-10-23 2018-04-24 Valtech Cardio, Ltd. Controlled steering functionality for implant-delivery tool
EP2911593B1 (en) 2012-10-23 2020-03-25 Valtech Cardio, Ltd. Percutaneous tissue anchor techniques
US9730793B2 (en) 2012-12-06 2017-08-15 Valtech Cardio, Ltd. Techniques for guide-wire based advancement of a tool
EP2948103B1 (en) 2013-01-24 2022-12-07 Cardiovalve Ltd Ventricularly-anchored prosthetic valves
WO2014134183A1 (en) 2013-02-26 2014-09-04 Mitralign, Inc. Devices and methods for percutaneous tricuspid valve repair
US10449333B2 (en) 2013-03-14 2019-10-22 Valtech Cardio, Ltd. Guidewire feeder
US9724195B2 (en) 2013-03-15 2017-08-08 Mitralign, Inc. Translation catheters and systems
WO2014189830A1 (en) 2013-05-20 2014-11-27 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Calcium channel agonists
US10070857B2 (en) 2013-08-31 2018-09-11 Mitralign, Inc. Devices and methods for locating and implanting tissue anchors at mitral valve commissure
WO2015059699A2 (en) 2013-10-23 2015-04-30 Valtech Cardio, Ltd. Anchor magazine
US9610162B2 (en) 2013-12-26 2017-04-04 Valtech Cardio, Ltd. Implantation of flexible implant
US10524910B2 (en) 2014-07-30 2020-01-07 Mitraltech Ltd. 3 Ariel Sharon Avenue Articulatable prosthetic valve
EP4331503A3 (en) 2014-10-14 2024-06-05 Edwards Lifesciences Innovation (Israel) Ltd. Leaflet-restraining techniques
CN110141399B (zh) 2015-02-05 2021-07-27 卡迪尔维尔福股份有限公司 带有轴向滑动框架的人工瓣膜
US20160256269A1 (en) 2015-03-05 2016-09-08 Mitralign, Inc. Devices for treating paravalvular leakage and methods use thereof
SG11201708397PA (en) 2015-04-30 2017-11-29 Valtech Cardio Ltd Annuloplasty technologies
WO2017117370A2 (en) 2015-12-30 2017-07-06 Mitralign, Inc. System and method for reducing tricuspid regurgitation
US10751182B2 (en) 2015-12-30 2020-08-25 Edwards Lifesciences Corporation System and method for reshaping right heart
US10531866B2 (en) 2016-02-16 2020-01-14 Cardiovalve Ltd. Techniques for providing a replacement valve and transseptal communication
US10702274B2 (en) 2016-05-26 2020-07-07 Edwards Lifesciences Corporation Method and system for closing left atrial appendage
GB201611910D0 (en) 2016-07-08 2016-08-24 Valtech Cardio Ltd Adjustable annuloplasty device with alternating peaks and troughs
GB201613219D0 (en) 2016-08-01 2016-09-14 Mitraltech Ltd Minimally-invasive delivery systems
EP4523659A3 (en) 2016-08-10 2025-06-04 Cardiovalve Ltd. Prosthetic valve with concentric frames
WO2018138500A1 (en) 2017-01-26 2018-08-02 Cyclacel Limited Process for preparing purine derivatives
US11045627B2 (en) 2017-04-18 2021-06-29 Edwards Lifesciences Corporation Catheter system with linear actuation control mechanism
US11793633B2 (en) 2017-08-03 2023-10-24 Cardiovalve Ltd. Prosthetic heart valve
US12064347B2 (en) 2017-08-03 2024-08-20 Cardiovalve Ltd. Prosthetic heart valve
US12458493B2 (en) 2017-09-19 2025-11-04 Cardiovalve Ltd. Prosthetic heart valve and delivery systems and methods
US10835221B2 (en) 2017-11-02 2020-11-17 Valtech Cardio, Ltd. Implant-cinching devices and systems
US11135062B2 (en) 2017-11-20 2021-10-05 Valtech Cardio Ltd. Cinching of dilated heart muscle
CN111655200B (zh) 2018-01-24 2023-07-14 爱德华兹生命科学创新(以色列)有限公司 瓣环成形术结构的收缩
EP3743014B1 (en) 2018-01-26 2023-07-19 Edwards Lifesciences Innovation (Israel) Ltd. Techniques for facilitating heart valve tethering and chord replacement
ES2974082T3 (es) 2018-07-12 2024-06-25 Edwards Lifesciences Innovation Israel Ltd Sistemas de anuloplastia y herramientas de bloqueo para los mismos
CN120531524A (zh) 2019-05-29 2025-08-26 爱德华兹生命科学创新(以色列)有限公司 组织锚固器存取系统和方法
US12364606B2 (en) 2019-07-23 2025-07-22 Edwards Lifesciences Innovation (Israel) Ltd. Fluoroscopic visualization of heart valve anatomy
CN114258313A (zh) 2019-08-28 2022-03-29 瓦尔泰克卡迪欧有限公司 低剖面可转向导管
EP4555942A3 (en) 2019-08-30 2025-07-30 Edwards Lifesciences Innovation (Israel) Ltd. Anchor channel tip
WO2021061945A1 (en) 2019-09-25 2021-04-01 Cardiac Implants Llc Cardiac valve annulus reduction system
CA3142906A1 (en) 2019-10-29 2021-05-06 Valtech Cardio, Ltd. Annuloplasty and tissue anchor technologies
GB202000901D0 (en) 2020-01-22 2020-03-04 Cyclacel Ltd Process
EP4103560A1 (en) * 2020-02-15 2022-12-21 Cipla Limited Novel salts of nilotinib and polymorphic forms thereof
CA3183115A1 (en) 2020-05-20 2021-11-25 Cardiac Implants Llc Reducing the diameter of a cardiac valve annulus with independent control over each of the anchors that are launched into the annulus
EP4167869B1 (en) 2020-06-19 2025-03-26 Edwards Lifesciences Innovation (Israel) Ltd. Self-stopping tissue anchors
US12357459B2 (en) 2020-12-03 2025-07-15 Cardiovalve Ltd. Transluminal delivery system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
EP1399446B1 (en) 2001-06-27 2005-08-03 Cyclacel Limited 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination
GB201001075D0 (en) 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms

Also Published As

Publication number Publication date
GB201001075D0 (en) 2010-03-10
WO2011089401A1 (en) 2011-07-28
ES2694289T3 (es) 2018-12-19
CN107400134A (zh) 2017-11-28
SG10201500451TA (en) 2015-03-30
ES2613716T3 (es) 2017-05-25
PL2526101T3 (pl) 2017-08-31
CN102985423A (zh) 2013-03-20
TR201816159T4 (tr) 2018-11-21
KR101860806B1 (ko) 2018-05-24
US20150148354A1 (en) 2015-05-28
KR101927083B1 (ko) 2018-12-10
SG182439A1 (en) 2012-08-30
US20130072504A1 (en) 2013-03-21
KR20120124450A (ko) 2012-11-13
JP2013518041A (ja) 2013-05-20
CN102985423B (zh) 2017-08-08
EP2526101A1 (en) 2012-11-28
PL3150602T3 (pl) 2019-03-29
EP2526101B1 (en) 2016-12-07
CN107400134B (zh) 2020-09-29
KR20180054933A (ko) 2018-05-24
EP3150602A1 (en) 2017-04-05
US9573951B2 (en) 2017-02-21
US8889861B2 (en) 2014-11-18
JP6114849B2 (ja) 2017-04-12
EP3150602B1 (en) 2018-08-01
JP2016128501A (ja) 2016-07-14

Similar Documents

Publication Publication Date Title
JP6114849B2 (ja) プリン誘導体の結晶性形態
AU2014286047B2 (en) Crystalline forms of ponatinib hydrochloride
WO2023212252A1 (en) Polymorphs of [2-(1h-indol-3-yl)-1h-imidazol-4-yl](3,4,5- trimethoxy)methanone and its salts
JP2025504276A (ja) 窒素含有縮合環系誘導体阻害剤の酸性塩又は結晶形及びその製造方法並びに応用
EA036295B1 (ru) Твердые формы замещенных 5,6-дигидро-6-фенилбензо[f]изохинолин-2-аминовых соединений
JP2024163194A (ja) フロピリミジン化合物の酸付加塩の結晶形
US20220002302A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
CN114026088A (zh) Jak2抑制剂的结晶形式
EP3083552B1 (en) Stable solid forms of enclomiphene and enclomiphene citrate
CN111499627A (zh) 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型
HK1173732A (en) Crystalline forms of a purine derivative
HK1173732B (en) Crystalline forms of a purine derivative
KR20250121978A (ko) Mnk 억제제의 고체 형태
TW201718538A (zh) 福奈孚匹坦的結晶形式
HK1231046B (en) Crystalline forms of a purine derivative
HK1231046A1 (en) Crystalline forms of a purine derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160608

R150 Certificate of patent or registration of utility model

Ref document number: 5951506

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250